Novartis AG
NVS
Positions held
Your positionsNVS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Novartis AG has a strong market position in the healthcare sector, with a market cap of approximately $267.6 billion, indicating investor confidence in its long-term growth potential.
- In Q2 2026, Novartis reported a revenue of $14.95 billion, reflecting an 11% increase compared to the previous quarter.
- The gross margin improved to 75.2% in Q2 2026, up from 74.4% in Q1 2026.
- The company's earnings growth has declined by 17% recently, raising concerns about its profitability and operational efficiency.
- The trailing P/E ratio stands at 21.27, which may indicate that the stock is overvalued compared to its earnings growth.
- The overall score for Novartis is a 'Sell' with a score of -10.00, suggesting negative market sentiment and potential risks ahead.
Fundamentals
| Market cap | $272.01B | Enterprise value | $313.81B | Trailing P/E | 21.62 | Forward P/E | 14.61 |
| PEG | 3.36 | Price / book | 6.55 | Beta | 0.47 | Dividend yield | 3.31% |
| Revenue growth | 0.8% | Earnings growth | -17.0% | Gross margin | 75.0% | Operating margin | 34.6% |
| Profit margin | 22.5% | ROE | 30.3% | ROA | 10.3% | Debt / equity | 1.17 |
| Current ratio | 0.86 | Free cash flow | $11.90B | Analyst recommendation | hold | Mean target | $155.01 |
| 52w high | $170.46 | 52w low | $121.57 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $15.0B | $13.5B | $13.9B | $14.4B | $14.8B |
| Op margin | 31.8% | 31.3% | 26.1% | 31.3% | 32.8% |
| Net income | $3.3B | $3.2B | $2.4B | $3.9B | $4.0B |
| Gross margin | 75.2% | 74.4% | 73.9% | 75.4% | 77.6% |
| Gross profit | $11.2B | $10.1B | $10.2B | $10.8B | $11.5B |
| Operating income | $4.8B | $4.2B | $3.6B | $4.5B | $4.9B |
- Revenue +11% vs prior quarter ($15.0B vs $13.5B).
- Gross margin 75.2% (was 74.4% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $56.7B | $51.7B | $46.7B | $43.5B | — |
| Op margin | 31.1% | 28.1% | 20.9% | 18.3% | — |
| Net income | $14.0B | $11.9B | $14.8B | $7.0B | — |
| Gross margin | 75.8% | 75.2% | 73.3% | 73.4% | — |
| Gross profit | $43.0B | $38.9B | $34.2B | $31.9B | — |
| Operating income | $17.6B | $14.5B | $9.8B | $7.9B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
2026-10-08 · Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.
2026-10-08 · NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
2026-10-08 · Market Chatter: Alphabet's Isomorphic Labs Seeks to Raise up to $50 Billion in Funding Round
2026-10-07 · Is Novartis (SWX:NOVN) Undervalued After New MS Trial Data Took Center Stage?
2026-10-07 · Sector Update: Healthcare Stocks Rise Late Afternoon
2026-10-07 · Sector Update: Healthcare Stocks Rise in Afternoon Trading
2026-10-07 · Novartis Receives FDA Approval for Rhapsido to Treat Symptomatic Dermographism
Price (daily)
Full chart · RSI · MACD · patterns